Solid dispersions in the development of a nimodipine floating tablet formulation and optimization by artificial neural networks and genetic programming

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 77, Issue 1, 2011, Pages 122-131

  Barmpalexis, Panagiotis ^a   Kachrimanis, Kyriakos ^a   Georgarakis, Emanouil ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Artificial neural networks; Controlled release; Effervescent floating tablets; Genetic programming; Nimodipine; Solid dispersions

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; NIMODIPINE; POVIDONE;

ARTICLE; ARTIFICIAL NEURAL NETWORK; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG RELEASE; EFFERVESCENT TABLET; INFRARED SPECTROSCOPY; MICROSCOPY; NUCLEAR REPROGRAMMING; PROCESS OPTIMIZATION; TABLET FORMULATION; X RAY DIFFRACTION;

ARTIFICIAL INTELLIGENCE; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; KINETICS; METHYLCELLULOSE; NEURAL NETWORKS (COMPUTER); NIMODIPINE; PHYSICOCHEMICAL PHENOMENA; POLYETHYLENE GLYCOLS; POLYMERS; POVIDONE; SOLUBILITY; TABLETS;

EID: 78650705344     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.09.017     Document Type: Article

References (37)

1. A. Grunenberg, B. Keil, and J.O. Henck Polymorphism in binary mixtures, as exemplified by nimodipine Int. J. Pharm. 118 1995 11 21
2. M.S. Langley, and E.M. Sorkin Nimodipine a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease Drugs 37 1989 669 699
3. W. Wu, Q. Zhou, H.B. Zhang, G.D. Ma, and C.D. Fu Studies on nimodipine sustained-release tablet capable of floating on gastric fluid with prolonged gastric resident time Acta Pharm. Sinica 32 1997 786 790
4. S.J. Wie, J.P. Liu, R. Lu, and W.J. Zheng Release kinetics and in vitro-in vivo correlation of nimodipine sustained-release soft gelatin capsule Chin. Pharm. J. 42 2007 852 856
5. P. Barmpalexis, F.I. Kanaze, K. Kachrimanis, and E. Georgarakis Artificial neural networks in the optimization of a nimodipine controlled release tablet formulation Eur. J. Pharm. Biopharm. 74 2010 316 323
6. M. Ichikawa, S. Watanabe, and Y. Miyake A new multiple unit oral floating dosage system. I: preparation and in vitro evaluation of floating and sustained-release kinetics J. Pharm. Sci. 80 1991 1062 1066
7. N. Ozdemir, S. Ordu, and Y. Ozkan Studies of floating dosage forms of furosemide: in vitro and in vivo evaluation of bilayer tablet formulation Drug Dev. Ind. Pharm. 26 2000 857 866
8. M.C. Gohel, and G. Manhapra-Sumitra Modulation of active pharmaceutical material release from a novel 'tablet in capsule system' containing an effervescent blend J. Control. Release 79 2002 157 164
9. S. Arora, J. Ali, A. Ahuja, R.K. Khar, and S. Baboota Floating drug delivery systems: a review AAPS PharmSciTech. 6 2005 E372 E390
10. T. Ozeki, H. Yuasa, and Y. Kanaya Controlled release from solid dispersion composed of poly(ethylene oxide)-Carbopol® interpolymer complex with various cross-linking degrees of Carbopol® J. Control. Release 63 2000 287 295
11. D.Q.M. Graig The mechanism of drug release from solid dispersions in water-soluble polymers Int. J. Pharm. 231 2002 131 144
12. FDA Guidance for Industry, PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, 2004.
13. FDA Guidance for Industry, Quality Systems Approach to Pharmaceutical CGMP Regulations, 2006.
14. International Conference on Harmonization (ICH) Proceedings, Q8(R2): Pharmaceutical Development, US FDA Federal Register, 2009.
15. F. Castillo, K. Marshall, J. Green, and A. Kordon A methodology for combing symbolic regression and design of experiments to improve empirical model building G. Bittencourt, G.L. Ramalho, Advances in Artificial Intelligence 2002 Springer Berlin Heidelberg 345 354
16. K. Takayama, M. Fujikawa, Y. Obata, and M. Morishita Neural network based optimization of drug formulation Adv. Drug Deliv. Rev. 55 2003 1217 1231
17. D.Q. Do, R.C. Rowe, and P. York Modelling drug dissolution from controlled release products using genetic programming Int. J. Pharm. 351 2008 194 200
18. J. Takahara, K. Takayama, and T. Nagai Multi-objective simultaneous optimization technique based on an artificial neural network in sustained release formulation J. Control. Release 49 1997 11 20
19. K. Takayama, A. Morva, M. Fujikawa, Y. Hattori, Y. Obata, and T. Nagai Formula optimization of theophylline controlled-release tablet based on artificial neural networks J. Control. Release 68 2000 175 186
20. European Pharmacopoeia, fifth ed., Monographs, Council of Europe, cop. Strasbourg, 2008, pp. 1981-1982.
21. P. Barmpalexis, F.I. Kanaze, and E. Georgarakis Developing and optimizing a validated isocratic reversed-phase high-performance liquid chromatography separation of nimodipine and impurities in tablets using experimental design methodology J. Pharm. Biomed. Anal. 49 2009 1192 1202
22. J. Timmermans, and A.J. Moës How well do floating dosage forms float? Int. J. Pharm. 62 1990 207 216
23. H.Y. Karasulu, F. Taneri, E. Sanal, T. Guneri, and G. Ertan Sustained release bioadhesive effervescent ketoconazole mictocapsules tabletted for vaginal delivery J. Microencapsul. 19 2002 357 362
24. L. Wang, and X. Tang A novel ketoconazole bioadhesive effervescent tablet for vaginal delivery: design, in vitro and in vivo evaluation Int. J. Pharm. 350 2008 181 187
25. N. Kavanagh, and O.I. Corrigan Swelling and erosion properties of hydroxypropylmethylcellulose (Hypromellose) matrices-influence of agitation rate and dissolution medium composition Int. J. Pharm. 279 2004 141 152
26. K. Tahara, K. Yamamoto, and T. Nishihata Overall mechanism behind matrix sustained release (SR) tablets prepared with hydroxypropyl methylcellulose J. Control. Release 35 1995 59 66
27. S.F. Ahrabi, G. Madsen, K. Dyrstad, S.A. Sande, and C. Graffner Development of pectin matrix tablets for colonic delivery of model drug ropivacaine Eur. J. Pharm. Sci. 10 2000 43 52
28. K. Kachrimanis, V. Karamyan, and S. Malamataris Artificial neural networks (ANNs) and modeling of powder flow Int. J. Pharm. 250 2003 13 23
29. J.R. Koza Genetic programming as means for programming computers by natural selection Stat. Comput. 4 1994 87 112
30. E. Spinoza, and A. Pozo Controlling the population size in genetic programming E. Cantu-Paz, J.A. Foster, K. Deb, L.D. Davis, R. Roy, U.M. O'Reilly, H.G. Beyer, R. Standish, G. Kendall, S. Wilson, M. Harman, J. Wegener, D. Dasgupta, M.A. Potter, A.C. Schultz, K.A. Dowsland, N. Jonoska, J. Miller, Genetic and Evolutionary Computation-GECCO 2003 Springer Berlin, Heidelberg 1975 1985
31. S. Agatonovic-Kustrin, and R. Beresford Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research J. Pharm. Biomed. Anal. 22 2000 717 727
32. X.C. Tang, M.J. Pikal, and L.S. Taylor A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers Pharm. Res. 19 4 2002 477 483
33. N.A. Urbanetz, and B.C. Lippold Solid dispersions of nimodipine and polyethylene glycol 2000: dissolution properties and physico-chemical characterization Eur. J. Pharm. Biopharm. 59 2005 107 118
34. M.M. Smikalla, and N.A. Urbanetz The influence of povidone K17 on the storage stability of solid dispersions of nimodipine and polyethylene glycol Eur. J. Pharm. Biopharm. 66 2007 106 112
35. G.Z. Papageorgiou, D. Bikiaris, E. Karavas, S. Politis, A. Docoslis, Y. Park, A. Stergiou, and E. Georgarakis Effect of physical state and particle size distribution on dissolution enhancement of Nimodipine/PEG solid dispersions prepared by melt mixing and solvent evaporation AAPS J. 8 4 2006 E623 E631
36. M. Vlachou, N. Hani, M. Efentakis, P.A. Tarantili, and A.G. Andreopoulos Polymers for use in controlled release systems: the effect of surfactants on their swelling properties J. Biomater. Appl. 15 2000 65 77
37. Y.B. Huang, Y.H. Tsai, W.C. Yang, J.S. Chang, P.C. Wu, and K. Takayama Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation Eur. J. Pharm. Biopharm. 58 2004 607 614